BOSTON, Oct. 18 (Reuters) - Shares of Nektar Therapeutics (NKTR.O: Quote, Profile, Research) fell 22 percent on Thursday in premarket trading after its partner Pfizer Inc. (PFE.N: Quote, Profile, Research) returned the rights to their inhaled diabetes drug Exubera amid sluggish sales.
